Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29303150 | 0.81 | GPR55 (0.36) | F2RL1LMNAHPGDMAPK1HTT | |
| SCHEMBL29303149 | 0.77 | ALDH1A1 (0.43) | F2RL1LMNAHPGDHTTTP53 | |
| SCHEMBL806276 | 0.77 | PIP4K2A (0.40) | F2RL1SCN9ACYP11B1CYP11B2LMNA | |
| SCHEMBL16722619 | 0.75 | F2RL1 (0.39) | F2RL1SCN9ACYP11B1CYP11B2LMNA | |
| SCHEMBL29303256 | 0.74 | F2RL1 (0.38) | F2RL1SCN9ACYP11B1CYP11B2 | |
| SCHEMBL23872465 | 0.72 | HTR2C (0.38) | F2RL1SCN9ACYP11B1CYP11B2LMNA | |
| SCHEMBL26014301 | 0.72 | CYP11B1 (0.40) | F2RL1SCN9ACYP11B1CYP11B2LMNA | |
| SCHEMBL24276943 | 0.72 | F2RL1 (0.35) | F2RL1 | |
| SCHEMBL16202646 | 0.71 | F2RL1 (0.43) | F2RL1 | |
| SCHEMBL28960638 | 0.71 | ERN1 (0.38) | F2RL1SCN9ACYP11B1CYP11B2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| WO-2021191359-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | F2RL1 1052/4885SCN9A 1744/4885CYP11B1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.